Navigation Links
Delcath to Present at the JMP Securities Healthcare Conference
Date:9/21/2010

NEW YORK, Sept. 21 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH) announced today that management will present at The Fifth Annual JMP Securities Healthcare Conference on Tuesday, September 28, 2010 at 11:30 a.m. ET in New York, NY. Mr. David McDonald, Chief Financial Officer, will provide an overview of the Company's business strategy and recent corporate developments.

Attendance at this conference is by invitation only. Delcath will offer a live audio webcast of its presentation, which may be accessed on the Investor Relations section of the Company's website at www.delcath.com.  An archived replay of the presentation will be available for 90 days, also at www.delcath.com.

About Delcath Systems

Delcath Systems, Inc. is a development stage, specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. Delcath recently concluded a Phase III metastatic melanoma study, and the Company is currently conducting a multi–arm Phase II trial to treat other liver cancers. The Company has not yet received FDA or any foreign regulatory approval for commercial sale of its system. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward–looking statements made by the Company or on its behalf. This news release contains forward–looking statements, which are subject t
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems Begins Data Analysis of Phase III Trial
11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... -- The number of people overdosing from opioid prescription ... percent of the workforce has misused prescription painkillers, according ... making opioid use a serious threat to employee safety. ... correct dosage with a valid prescription, subtle impairment may ... Safety Council released a guide for employers, ...
(Date:7/22/2014)... July 22, 2014 BiologicTx ® today ... first 3-way Kidney Paired Donation transplant exchange utilizing BiologicTx,s ... on July 9 at the Miami Transplant Institute, located ... Kidney Paired Donation (KPD) ... compatible for kidney transplant with one another due to ...
(Date:7/22/2014)... -- Elekta (NSE:EKTAb) and Royal Philips (NYSE: ... Trust ( Manchester, UK ), a specialist ... to develop the clinical value of an integrated magnetic ... system would, in principle, improve the practice of radiotherapy ... "The Christie was an essential participant in the project ...
Breaking Medicine Technology:5 things employers should know about prescription painkiller use 25 things employers should know about prescription painkiller use 3BiologicTx Paired Donation Aids In Successful Kidney Transplants 2BiologicTx Paired Donation Aids In Successful Kidney Transplants 3The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 2The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 3The Christie Hospital joins Elekta and Philips research consortium to develop MRI-guided radiation therapy system for cancer treatment 4
... Lilly and Company (NYSE: LLY ) announced ... Lilly to access innovation being developed outside the company,s ... independent venture capital firms participating in the Mirror Portfolio ... stage of their development. The first is a molecule ...
... 2011 Mylan Inc. (Nasdaq: MYL ) ... launched Voriconazole Tablets, 50 mg and 200 mg, under ... Inc. Mylan was the first company to have filed ... for Voriconazole Tablets and was awarded 180 days of ...
Cached Medicine Technology:Lilly Marks Major Milestone for Mirror Portfolio with Agreement by Independent Fund to License First Two Investigational Medicines 2Lilly Marks Major Milestone for Mirror Portfolio with Agreement by Independent Fund to License First Two Investigational Medicines 3Lilly Marks Major Milestone for Mirror Portfolio with Agreement by Independent Fund to License First Two Investigational Medicines 4
(Date:7/22/2014)... Brand journalism tactics for ... Ragan Communications 2014 Health Care PR and Marketing ... consecutive year that MediaSource placed in the finalist category ... the winning MediaSource team last year. This year the ... against three other contenders that include AMF Media Group ...
(Date:7/22/2014)... HealthDay Reporter , MONDAY, July 21, 2014 (HealthDay ... high school may take fewer health risks than their peers ... of low-income Los Angeles teens, found that those who attended ... binge-drink, have multiple sex partners or take certain other health ... kids" being more likely to go to good schools, researchers ...
(Date:7/22/2014)... team has identified protein "signatures" of genetic mutations ... cause of cancer deaths after lung cancer. , ... current issue of the journal Nature ... cancer, "will enable new advances" in diagnosing and ... a first-of-its-kind paper. I think it,s a very ...
(Date:7/22/2014)... July 22, 2014 SkillSurvey Inc., ... that help employers make better hiring decisions, will ... to improve the engagement and retention of contingent ... Recruitment’s IMAGE 2014 Conference being held in Orlando, ... include a case study featuring Metro Health, a ...
(Date:7/22/2014)... 2014 The purpose of this ... specific market segment called disposable medical supplies. Disposable ... global healthcare equipment and supplies sector. The disposable ... syringes, disposable medical catheters, wound care products, isolation ... products, blood glucose test strips, lancets, lancing devices, ...
Breaking Medicine News(10 mins):Health News:MediaSource Brand Journalism Returns to Best Health Care Agency Competition in Ragan Communications Health Care Awards 2Health News:MediaSource Brand Journalism Returns to Best Health Care Agency Competition in Ragan Communications Health Care Awards 3Health News:Good Schools May Be Good for a Teen's Health, Too 2Health News:Good Schools May Be Good for a Teen's Health, Too 3Health News:Vanderbilt discovery may advance colorectal cancer diagnosis and treatment 2Health News:SkillSurvey to Present Research on Contingent Workers at National Association for Health Care Recruitment IMAGE 2014 Conference 2Health News:Growth of Disposable Medical Supplies Market to 2019 Report Available at RnRMarketResearch.com 2Health News:Growth of Disposable Medical Supplies Market to 2019 Report Available at RnRMarketResearch.com 3Health News:Growth of Disposable Medical Supplies Market to 2019 Report Available at RnRMarketResearch.com 4Health News:Growth of Disposable Medical Supplies Market to 2019 Report Available at RnRMarketResearch.com 5
... areas of B.C. are up to twice as likely ... better-off areas, a University of British Columbia study has ... online journal Public Library of Science ONE , ... are more vulnerable to death from chronic disease, particularly ...
... N.Y., Jan. 8 Davis Vision, Inc., headquartered in ... of sales for its Northern division. In this new ... Davis Vision,s national new business development. "Mike will be ... said Tom Davis, Davis Vision,s executive vice president and ...
... Supplement Health and Education Act Mandates Label ... , WASHINGTON, Jan. 8 In response ... supplement regulation, the Natural Products Association,s Executive ... statement:Increased scrutiny by professional sports leagues on ...
... illness can lead to poorer quality of lifeparticularly ... help teens cope with their conditions. , Two ... professor of medicine, and Sian Cotton, PhD, research ... investigated how adolescents with inflammatory bowel disease (IBD)a ...
... on pets during National Glaucoma month. , ... Tampa, ... Month, Florida Veterinary Specialists (FVS) are spreading the word ... as humans.    , , ,"When eyes go bad, they often do so ...
... much more likely to be deadly for women and African-Americans, ... for only part of the differences for such patients compared ... in the Jan. 1 issue of the journal Cancer ... If age, tumor type, and stage of the disease upon ...
Cached Medicine News:Health News:Mortality rates higher for heart disease patients in poorer B.C. neighborhoods 2Health News:Davis Vision, Inc. Names Michael Ehrle Divisional Vice President of Sales 2Health News:Natural Products Association Advocates Strength of Dietary Supplement Law 2Health News:Spirituality may help adolescents cope with chronic illness 2Health News:Spirituality may help adolescents cope with chronic illness 3Health News:Glaucoma Awareness Not Just for Humans 2Health News:Glaucoma Awareness Not Just for Humans 3Health News:Why Bladder Cancer Is Deadlier for Some 2Health News:Why Bladder Cancer Is Deadlier for Some 3Health News:Why Bladder Cancer Is Deadlier for Some 4
MicroAmp Full Plate Covers, which are manufactured from PCR-compatible rubber, are non-sterile, autoclavable and guaranteed reusable up to five times....
96-Well PCR Plate Sealing Mat...
Inquire...
Inquire...
Medicine Products: